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Abstract 
Background. S-1, an oral fluoropyrimidine, is usually given for 4 weeks (80 mg/m
2
/day) 
followed by a 2-week rest. However, compliance with this regimen is unsatisfactory 
because of adverse events such as leukopenia, anorexia, and nausea. To reduce adverse 
effects and improve compliance, we studied a “5-day on/2-day off” low-dose regimen 
of S-1 and evaluated pharmacokinetics in patients with non-small-cell lung cancer 
(NSCLC). 
Methods. Twelve patients with NSCLC were divided into 2 groups and received S-1 in 
a dose of 25 mg twice daily (level 1, n = 6) or 40 mg twice daily (level 2, n = 6) for 5 
consecutive days followed by a 2-day rest (5 days on/2 days off) every week. Plasma 
5-fluorouracil (5-FU) concentrations were measured.  
Results. The maximum concentration in plasma and the area under the plasma 
concentration-time curve from 0 to 9 h were respectively 55.3 ± 21.1 ng/ml and 290.2 ± 
95.7 ng・hr/ml for level 1, as compared with 104.2 ± 33.5 ng/ml and 541.9 ± 232.3 ng・
hr/ml for level 2. These values were similar to those previously reported for a 
continuous intravenous infusion of 5-FU. Adverse events were grade 1 fatigue (n = 1 in 
each group) and anorexia (n = 1 in each group).  
Conclusions. A “5-day on/2-day off” low-dose (40 mg twice daily) regimen of S-1 is 
feasible for the treatment of NSCLC, with acceptable plasma 5-FU concentrations and 
minimal adverse effects. A phase II or III trial of this regimen in an adjuvant setting is 
warranted in patients with NSCLC.  
 
Keywords: chemotherapy, low-dose administration, non-small-cell lung cancer, oral 
anticancer fluoropyrimidine agent, pharmacokinetic study, S-1.  
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TEXT 
Introduction  
Lung cancer is the leading cause of cancer-related mortality in many countries 
[1]. For non-small-cell lung cancer (NSCLC), adjuvant chemotherapy is recommended 
after complete resection in patients with pathological stage IB to IIIA disease. The West 
Japan Study Group for Lung Cancer Surgery reported that survival after complete 
resection was significantly prolonged by adjuvant treatment with oral uracil-tegafur 
(UFT) as compared with observation alone in patients with stage I, II, or III NSCLC [2]. 
Adjuvant chemotherapy with UFT for 2 years was also shown to improve survival in 
patients with completely resected pathological stage I adenocarcinoma of the lung [3]. 
Although another study [4] showed no significant improvement in the postoperative 
survival of patients with pathological stage I NSCLC, a meta-analysis reported that 
postoperative adjuvant chemotherapy with UFT prolonged 5- and 7-year survival in 
Japanese patients who primarily had pathological stage I adenocarcinoma of the lung 
[5]. 
S-1 is an oral anticancer fluoropyrimidine agent that combines the 
5-fluorouracil (5-FU) prodrug tegafur with two enzyme inhibitors, 
5-chloro-2,4-dihydropyrimidine (CDHP) and potassium oxonate [6]. CDHP inhibits 
dihydropyrimidine dehydrogenase, and potassium oxonate suppresses pyrimidine 
phosphoribosyltransferase. Consequently, 5-FU concentrations after oral administration 
of S-1 are higher than those after than a protracted intravenous infusion of 5-FU given 
at a dose equimolar to the tegafur in S-1, with no increase in the incidence of 
gastrointestinal toxicity [7, 8]. S-1 is usually given for 4 weeks (80 mg/m
2
/day) 
followed by a 2-week rest. However, compliance with regimen is often unsatisfactory 
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because of adverse events such as anorexia, nausea, and leukopenia [9, 10]. To reduce 
adverse effects and improve compliance, we studied a “5-day on/2-day off” low-dose 
regimen of S-1 and evaluated pharmacokinetics in patients with non-small-cell lung 
cancer (NSCLC).  
 
Patients and Methods 
Patient eligibility 
All patients were enrolled at the Department of Thoracic Surgery, Kyoto 
University Hospital. Eligible patients had histopathologically proven, completely 
resected lung cancer (pathological stage I, II, or IIIA) and a performance status (Eastern 
Cooperative Oncology Group) of 0 or 1. Recurrent disease after complete resection was 
included. The hematological criteria for enrollment were as follows: leukocyte count, 
≥4,000/mm3; neutrophil count, ≥2,000/mm3; platelet count, ≥100,000/mm3; hemoglobin 
concentration, ≥10.0 g/dl; serum bilirubin concentration, ≤1.5 mg/dl; serum aspartate 
aminotransferase and alanine aminotransferase concentrations, no more than twice the 
upper limit of normal; serum creatinine concentrations, ≤1.5 mg/dl; creatinine clearance, 
≥60 ml/min or higher; and life expectancy, ≥3 months. The protocol was approved by 
our institutional review board, and each patient gave written informed consent 
(approved by Kyoto University Graduate School and Faculty of Medicine, Ethics 
Committee, registration number C-74). 
 
Treatment schedule  
S-1 was administered orally twice daily, after breakfast and dinner. For each 
cycle of treatment, S-1 was given for 5 consecutive days followed by a 2-day rest (5 
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days on/2 days off) for 4 weeks. Patients received S-1 in a dose of 25 mg twice daily 
(level 1) or 40 mg twice daily (level 2). Treatment was repeated until the development 
of disease progression or unacceptable toxicity. Patients had to have a leukocyte count 
of ≥3,000/mm3, a neutrophil count of ≥1,500/mm3, and a platelet count of ≥75,000/mm3 
to receive the next cycle of treatment. If grade 2 or higher hematologic or 
nonhematologic toxicity occurred during any treatment cycle, S-1 was discontinued and 
withheld until such toxicity resolved. The eligibility criteria for study entry had to be 
met before the resumption of treatment.  
 
Specimen collection to assess 5-FU concentrations in plasma 
Peripheral blood samples were collected on day 5, before treatment in the 
morning and 2, 4, and 9 h after treatment. Peripheral blood samples (8 ml per sample) 
were collected into heparinized tubes and centrifuged at 3,000 rpm for 10 min at 5˚C; 
the plasma was separated and samples were stored at -20˚C.  
 
Drug assay 
Concentrations of 5-FU were analyzed as described by Matsushima et al. [11]. 
Tegafur was extracted with dichloromethane from each sample and analyzed using a 
high-performance liquid chromatograph equipped with an ultraviolet absorption 
spectrometer. 5-FU was extracted with ethyl acetate from the residue obtained after 
dichloromethane extraction. It was then analyzed using a negative ion chemical 
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Standard pharmacokinetic parameters of 5-FU were calculated on the basis of 
the plasma concentration-time profiles obtained from the 4 samples for each patient who 
received level 1 (S-1 25 mg) or level 2 (S-1 40 mg). Calculations were done with a 
non-compartmental method, using the computer program WinNonlin, version 5.2 
(Pharsight Corporation, Mountain View, CA, USA). The maximum concentration in 
plasma (Cmax) was obtained directly from the concentration-time data. The area under 
the plasma concentration-time curve was calculated using the trapezoidal rule from 0 to 
9 h (AUC0-9). The values are expressed as the means ± standard deviation (SD) for the 6 
patients per group. 
 
Evaluation of toxicity 
Adverse events were graded according to the National Cancer Institute 




Twelve patients were enrolled in this study and divided into 2 groups (level 1, 
6 patients; level 2, 6 patients). The characteristics of the patients are shown in Table 1-1. 
Five of the 6 patients given level 1 and 3 of the 6 patients given level 2 had recurrent 
disease at study entry. All 8 of these patients with recurrent disease had previously 
received at least one other regimen of chemotherapy (Table 1-2). The other 4 patients 
did not have recurrent disease or a history or prior chemotherapy at study entry. The 
mean daily dose per body surface area (BSA) was 33.6 mg/m
2
 (25.2 - 41.4 mg/m
2
) for 
level 1 and 47.8 mg/m
2
 (43.5 - 56.4 mg/m
2
) for level 2. 
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Pharmacokinetics of 5-FU after S-1 administration 
The time courses of plasma 5-FU concentrations in the level 1 and 2 groups are 
shown in Fig. 1. On the basis of plasma 5-FU concentrations, Cmax and AUC0-9 were 
respectively 55.3 ± 21.1 ng/ml and 290.2 ± 95.7 ng・hr/ml at level 1, as compared with 
104.2 ± 33.5 ng/ml and 541.9 ± 232.3 ng・hr/ml at level 2 (Table 2). 
 
Toxicity  
Grade 1 fatigue (n=1 in each group) and anorexia (n=1 in each group) occurred 
as adverse events (Table 3).  
 
Compliance  
In the level 1 group (25 mg twice daily), S-1 treatment was discontinued 
because of progressive disease in 3 of the 6 patients at weeks 16, 35, and 60, 
respectively. All 3 of these patients had recurrent disease at study entry. One patient 
refused to continue S-1 treatment because of grade 1 fatigue at week 43, and another 
refused S-1 treatment at week 2 despite no toxicity. One patient continued to receive 
S-1 for more than 68 weeks with no adverse events. This patient (stage IIB) was the 
only one without recurrent disease at study entry in the level 1 group and has not shown 
any signs of recurrence at the time of this writing.  
At level 2 (40 mg twice daily), S-1 was discontinued because of progressive 
disease in 2 of 6 patients at weeks 4 and 15, respectively. These 2 patients had recurrent 
disease at study entry. Another patient refused to continue treatment with S-1 because 
of grade 1 fatigue at week 12. The 3 other patients continued to receive S-1 without any 
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adverse events for more than 35, 44, and 51 weeks, respectively. These patients, who 
had pathological stage IB, IIIA, and IIIA, respectively, did not have recurrent disease at 
study entry and have not shown any signs of recurrence. Thus, all 4 patients without 
recurrent disease at study entry continued to receive S-1 without recurrence or adverse 
events for 35 to 68 weeks. 
 
Discussion 
Although UFT is effective as postoperative adjuvant chemotherapy in 
early-stage NSCLC, its efficacy for advanced disease remains to be confirmed [12]. In 
patients with completely resected pathological stage II to IIIA NSCLC, cisplatin-based 
chemotherapy is recommended for adjuvant chemotherapy on the basis of the results of 
randomized controlled trials [13-16]. In one study, however, the significant 
improvement in 5-year survival with cisplatin-based chemotherapy was not maintained 
after longer follow-up, mainly because a rise in noncancer-related mortality in patients 
who received cisplatin [17]. Thus, concern about late toxicity associated with 
cisplatin-based chemotherapy has highlighted the need for less toxic chemotherapy in a 
postoperative adjuvant setting. As stated above, S-1 is usually given daily for 4 weeks 
(80 mg/m
2
/day) followed by a 2-week rest, repeated for 4 cycles. However, compliance 
with this regimen is often not satisfactory because of adverse events such as anorexia, 
nausea, and leukopenia. In one Japanese Phase II trial [10] of S-1 alone administered 
according to this schedule to 59 eligible patients with advanced lung cancer, grade 3 or 
higher toxicity included anorexia in 6 patients (10.2%), diarrhea in 5 (8.5%), 
neutropenia in 4 (6.8%), and malaise in 4 (6.8%). Only 10 (16.9%) of the 59 patients 
completed the fourth cycle of chemotherapy as scheduled, and toxicity was the reason 
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for treatment withdrawal in 7 of the 28 patients who received only one cycle of S-1. 
Recently, Yano et al. reported a feasibility study of postoperative adjuvant 
chemotherapy with S-1 in patients with NSCLC [18]. Each treatment cycle consisted of 
S-1 in a dose of 80 to 120 mg/day (80 mg/m
2
/day) for 2 weeks followed by a 1-week 
rest. Patients were scheduled to receive 8 cycles of chemotherapy. The total and daily 
doses of S-1 in their study were similar to those in other studies [9, 10]. Eight courses of 
chemotherapy were completed as scheduled by 17 (56.7%) of the 30 patients. The 
completion rate of chemotherapy was only 42.9% in patients 70 years or older, as 
compared with 78.6% in those younger than 70 years. The compliance rate in the 
elderly patients is considered low for adjuvant chemotherapy. It thus remains unclear 
whether the recommended dose and treatment schedule for S-1 in an adjuvant setting 
should be the same as that for patients with advanced disease.  
Ideally, drugs and treatment schedules used for postoperative adjuvant 
chemotherapy should have low toxicity and good compliance. Sakuramoto et al. [19] 
demonstrated that S-1 is an effective adjuvant treatment in patients with curatively 
resected gastric cancer as compared with surgery alone in a large randomized trial 
performed in Japan. In that study, S-1 (80 mg/m
2
/day) was given for 4 weeks followed 
by a 2-week rest. Although overall survival was significantly better in the S-1 group, 
grade 3 or 4 adverse events such as anorexia, nausea, and leukopenia were more 
common in the S-1 group than in the surgery alone group. Among 517 patients 
scheduled to receive S-1 for 12 months, 71 (13.7%) refused to continue treatment 
because of adverse events or other factors, and 72 (13.9%) discontinued treatment at the 
investigators’ discretion because of adverse events or complications. Overall, the dose 
of S-1 was decreased in 219 of the 517 patients (42.4%) who received S-1, as well as in 
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158 (46.5%) of the 340 patients who continued S-1 treatment for 12 months. On the 
basis of these results, we decided to evaluate a new regimen of S-1 designed to decrease 
adverse events and improve compliance. We not only lowered the daily dose of S-1 to 
50 or 80 mg/day, but also used a “5-day on/2-day off” treatment schedule. At level 2 
(80 mg/day) the Cmax of 5-FU was 104.2 ± 33.5 ng/ml and the AUC0-9 was 541.9 ± 
232.3 ng・hr/ml. A pharmacokinetic study of S-1 at a standard dose of 80 mg/m2/day in 
patients with advanced cancer (gastric, colorectal, and breast) [20] reported that the 
Cmax of 5-FU was 128.5 ± 41.5 ng/ml with an AUC0-14 of 723.9 ± 272.7 ng・hr/ml. 
Since dosage forms of S-1 was 40 mg and 25 mg, two dosage levels of low dose S-1, 80 
mg/day (40 mg, twice a day) and S-1 50 mg/day (25 mg, twice a day) was used in this 
study. Although the dose of S-1 in our study was lower than the standard dose, our 
pharmacokinetic analysis showed that Cmax and AUC were comparable to those in 
patients who received a standard regimen of S-1. Moreover, in another pharmacokinetic 
study in patients with advanced colorectal cancer who received 5-FU (300 mg/m
2
/day) 
by continuous venous infusion for 26 weeks [21], the 5-FU concentration at steady state 
was 94 ± 25 ng/ml, which was also similar to the Cmax of level 2 (104.2 ± 33.5 ng/ml) 
in the present study.  
In conclusion, our results show that a “5-day on/2-day off” low-dose regimen 
of S-1 (40 mg, twice daily) is feasible for the treatment of NSCLC, with acceptable 
plasma 5-FU concentrations and minimal adverse effects. A phase II or III trial of this 
regimen in an adjuvant setting is warranted in patients with NSCLC.  
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Figure legend 





[1] Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 
2006; 56: 106-30. 
[2] Wada H, Hitomi S, Teramatsu T. Adjuvant chemotherapy after complete 
resection in non-small-cell lung cancer. West Japan Study Group for Lung Cancer 
Surgery. J Clin Oncol 1996; 14: 1048-54. 
[3] Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant 
chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004; 
350: 1713-21. 
[4] Nakagawa M, Tanaka F, Tsubota N, Ohta M, Takao M, Wada H. A 
randomized phase III trial of adjuvant chemotherapy with UFT for completely resected 
pathological stage I non-small-cell lung cancer: the West Japan Study Group for Lung 
Cancer Surgery (WJSG)--the 4th study. Ann Oncol 2005; 16: 75-80. 
[5] Hamada C, Tanaka F, Ohta M, et al. Meta-analysis of postoperative adjuvant 
chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol 2005; 23: 
4999-5006. 
[6] Shirasaka T, Shimamato Y, Ohshimo H, et al. Development of a novel form of 
an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective 
cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996; 
Shoji 
 - 12 - 
7: 548-57. 
[7] van Groeningen CJ, Peters GJ, Schornagel JH, et al. Phase I clinical and 
pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol 
2000; 18: 2772-9. 
[8] Yamada Y, Hamaguchi T, Goto M, et al. Plasma concentrations of 
5-fluorouracil and F-beta-alanine following oral administration of S-1, a 
dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with 
protracted venous infusion of 5-fluorouracil. Br J Cancer 2003; 89: 816-20. 
[9] Furuse K, Kawahara M, Hasegawa K, et al. Early phase II study of S-1, a new 
oral fluoropyrimidine, for advanced non-small-cell lung cancer. Int J Clin Oncol 2001; 
6: 236-41. 
[10] Kawahara M, Furuse K, Segawa Y, et al. Phase II study of S-1, a novel oral 
fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 2001; 85: 939-43. 
[11] Matsushima E, Yoshida K, Kitamura R, Yoshida K. Determination of S-1 
(combined drug of tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate) and 
5-fluorouracil in human plasma and urine using high-performance liquid 
chromatography and gas chromatography-negative ion chemical ionization mass 
spectrometry. J Chromatogr B Biomed Sci Appl 1997; 691: 95-104. 
[12] Shimizu E, Kimura K, Sone S, et al. A phase II study of UFT in non-small cell 
lung cancer. Gan to kagaku ryoho 1986; 13: 2970-3. 
[13] Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste 
J. Cisplatin-based adjuvant chemotherapy in patients with completely resected 
non-small-cell lung cancer. N Engl J Med 2004; 350: 351-60. 
[14] Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. 
Shoji 
 - 13 - 
observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352: 2589-97. 
[15] Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin 
versus observation in patients with completely resected stage IB-IIIA non-small-cell 
lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a 
randomised controlled trial. Lancet Oncol 2006; 7: 719-27. 
[16] Strauss GM, Herndon JE, 2nd, Maddaus MA, et al. Adjuvant paclitaxel plus 
carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 
9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and 
North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008; 26: 5043-51. 
[17] Arriagada R, Dunant A, Pignon JP, et al. Long-term results of the international 
adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected 
lung cancer. J Clin Oncol 2010; 28: 35-42. 
[18] Yano T, Yamazaki K, Maruyama R, et al. Feasibility study of postoperative 
adjuvant chemotherapy with S-1 (tegaful, gimeracil, oteracil potassium) for non-small 
cell lung cancer-LOGIK 0601 study. Lung cancer 67: 184-7. 
[19] Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for 
gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810-20. 
[20] Hirata K, Horikoshi N, Aiba K, et al. Pharmacokinetic study of S-1, a novel 
oral fluorouracil antitumor drug. Clin Cancer Res 1999; 5: 2000-5. 
[21] Jodrell DI, Stewart M, Aird R, et al. 5-fluorouracil steady state 
pharmacokinetics and outcome in patients receiving protracted venous infusion for 
advanced colorectal cancer. Br J Cancer 2001; 84: 600-3. 
 
 
Table 1-1. Patient characteristics 
 
  Level 1 (S-1 25 mg, twice daily) Level 2 (S-1 40 mg, twice daily) 
Enrolled patients  6 6 
Age, years    
 Median 79.2 65.3 
 Range 60-87 61-75 
Sex     
 Male/Female 3/3 5/1 
ECOG performance status    
 0/1 5/1 6/0 
Stage    
 IA (with recurrence) 3 (3)  1 (1) 
 IB (with recurrence) 1 (1) 2 (1) 
 IIA (with recurrence) 0 (0) 0 (0) 
 IIB (with recurrence) 1 (0) 0 (0) 
 IIIA (with recurrence) 1 (1) 3 (1) 
Type of Surgery    
 Pneumonectomy/Lobectomy/Segmentectomy/Partial* 0/4/1/1 1/3/2/0 
Histology    
 Adeno/ Squamous/ Large 4/1/1 4/2/0 
Average daily dose per BSA** (mg/m2)  33.6 (25.2 - 41.4) 47.8 (43.5 - 56.4) 
*Partial: partial resection, **BSA: body surface area
Table 1-2. Characteristics of patients with recurrent disease at study entry 
 
 Onset of recurrent disease 
after surgery (months after 
operation) 
Recurrent site Previous chemotherapies 
(as adjuvant or for 
recurrent disease) 
Level 1 (S-1 25 mg, twice daily, n = 5)    
 Patient 1 (79 y.o, female) 22 Local (pleura) UFT as adjuvant, UFT+GEM, 
gefitinib for recurrence 
 Patient 2 (84 y.o, female) 11 Local (lung) CBDCA, UFT, gefitinib for 
recurrence 
 Patient 3 (87 y.o, male) 13 Local (lung) UFT as adjuvant, VNR for 
recurrence 
 Patient 4 (87 y.o, female) 68 Local (lung) UFT as adjuvant, gefitinib for 
recurrence 
 Patient 5 (60 y.o, male) 30 Distant (brain) CBDCA + PAC, UFT as 
adjuvant 
Level 2 (S-1 40 mg, twice daily, n = 3)    
 Patient 1 (62 y.o, female) 36 Local (lung) UFT as adjuvant 
 Patient 2 (75 y.o, male) 5 Loco-regional (lymph nodes, pleura) CBDCA+GEM, DOC, VNR 
or recurrent disease) 
 Patient 4 (61 y.o, male) 6 Distant (retroperitoneal)  CDDP+VNR as adjuvant, Doc 
for recurrence 
GEM: Gemcitabine, CBDCA: Carboplatin, VNR: Vinorelbine, PAC: Paclitaxel, DOC: Docetaxel, CDDP: cisplatin. 
Table 2. Pharmacokinetic parameters 
 
 AUC0-9 Cmax BSA AUC0-9/BSA 





Level 1 (S-1 25 mg*) 290.2 ±95.7 55.3 ±21.1 1.524 ±0.270 200.6 ±87.2 
Level 2 (S-1 40 mg*) 541.9 ±232.3 104.2 ±33.5 1.688 ±0.164 335.7 ±186.5 
 









Table 3. Toxicity 
 
NCI-CTC grade Level 1 (S-1 25 mg, twice daily)  Level 2 (S-1 40 mg, twice daily) Level 1-2 
 1 2 3 4  1 2 3 4 Grade 3/4 
Hematologic           
Leukopenia 0 0 0 0  0 0 0 0 0 
Neutropenia 0 0 0 0  0 0 0 0 0 
Anemia 0 0 0 0  0 0 0 0 0 
Thrombocytopenia 0 0 0 0  0 0 0 0 0 
Nonhematologic           
Anorexia 1 0 0 0  1 0 0 0 0 
Nausea/Vomiting 0 0 0 0  0 0 0 0 0 
AST/ALT 0 0 0 0  0 0 0 0 0 
General fatigue 1 0 0 0  1 0 0 0 0 
 Diarrhea 0 0 0 0  0 0 0 0 0 
 






















L Level 1 (S-1 25 mg*)
Level 2 (S-1 40 mg*)
